Navigation Links
LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Date:6/4/2009

COPENHAGEN, June 4 /PRNewswire/ -- Santaris Pharma today announced that the cancer drug EZN-2968 - an inhibitor of HIF-1alpha, jointly developed by Enzon Pharmaceuticals and Santaris Pharma A/S - was well tolerated and showed early signs of clinical benefit in previously treated cancer patients with advanced malignancies. EZN-2968 is being evaluated in patients with solid tumors and lymphoma. The study data, which was presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting in Florida last week, demonstrated that EZN-2968 is well tolerated, and that early signs of clinical benefit - prolonged stable disease - were observed in several patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

"We have yet to see a dose limiting toxicity and we continue to be encouraged by the early clinical signals in this program," said Jeffrey H. Buchalter, Enzon's Chairman and Chief Executive Officer. "The duration of clinical benefit in certain histologies has exceeded our expectations at this phase of development. We look forward to advancing this promising compound into Phase II trials later this year, once a dose is determined."

"We are encouraged by the progress in the development of this LNA-based HIF-1 alpha inhibitor. The fact that LNA-based RNA inhibitors are beginning to show signs of clinical benefit in cancer patients is very rewarding and is further evidence of the potential of our LNA Drug Platform to generate effective and safe medicines to treat important diseases across a broad range of therapeutic areas," said S0ren Tulstrup, President & CEO of Santaris Pharma A/S.

HIF-1 alpha is a well-validated target in many common solid tumors. EZN-2968 is the first drug candidate to target the HIF-1 transcription factor, which regulates expression of many key genes i
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs
3. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
4. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
5. According to AlphaDetail, Inc. Merck and Tibotec Therapeutics Lead Among Infectious Disease Specialists
6. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
7. AlphaVax Announces New CMV Advisory Board
8. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... ... recently presented new data on the relationship of genetics and hypertension at the ... on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... increasing its investment in the development and manufacture of highly valued cardiac markers ... company’s scientific team's extensive expertise with protein chemistry has led to the development ...
(Date:8/26/2015)... BEIJING , August 26, 2015 ... DiaCardio wins 1 st place  Wayerz ... led in Israel by venture capital fund ... countries including the US, China , ... Latin America .  Impressive achievement for the Israeli ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical Trial Management ... local sponsors in southern California. The Clinical Trial Management Expert CRO seeks to introduce ... pathways., , Stem Cell Meeting on the Mesa ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM), today ... CYT387 JAK1/JAK2 inhibitor program demonstrating that CYT387 possesses ... may provide significant clinical advantages. CYT387 is currently ... at Mayo Clinic in patients with myelofibrosis. The ...
... Oct. 1 Collagen Matrix, Inc., the leader in ... has received FDA,s 510(k) clearance of a new Collagen ... in oral surgical procedures involving guided tissue and bone ... Membrane is a nonfriable, conformable, resorbable, membrane matrix consisting ...
... Sept. 30 Vaccinogen, Inc. has appointed veteran biotechnology ... Officer to guide it through its next stage of ... as the company proceeds to finance and launch our ... Jr., Ph.D., Vaccinogen,s Founder & Chairman and inventor of ...
Cached Biology Technology:YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology 2Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO 2
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... NEW YORK , Aug. 12, 2015 /PRNewswire/ ... how hackers can attack Android phones to steal ... identifies the increasing availability of fingerprint scanners on ... of utmost concern. To secure biometrics on mobile ... platform to augment these convenient authentication systems with ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... 25, 2010An insightful and in-depth presentation of the most ... pediatric interstitial lung disease (ILD) is presented in a ... Pediatric Allergy, Immunology, and Pulmonology (PED), a peer-reviewed ... ). The entire issue is available free online. ( ...
... E. coli O157:H7 is present but rare in some ... area often referred to as the nation,s "salad bowl," reports ... The researchers, who are nearing completion of a massive ... coli O157:H7 near Central Coast farms, presented their findings ...
... WALNUT CREEK, Calif. More than a thousand microbial ... the past 15 years to better understand their roles ... cleanup. Conservative estimates suggest roughly 10,000 microbial genomes will ... genomic standards have not caught up with the technological ...
Cached Biology News:Comprehensive overview of Children's Interstitial Lung Disease (chILD) in special issue of Pediatric Allergy, Immunology, and Pulmonology 2E. coli 0157:H7 present but not common in wildlife of nation's salad bowl 2E. coli 0157:H7 present but not common in wildlife of nation's salad bowl 3DOE JGI produces new QC tool for microbial genomes 2DOE JGI produces new QC tool for microbial genomes 3DOE JGI produces new QC tool for microbial genomes 4
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
Hybridizer (220 V) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... in vascular proliferation, adhesion, and wound repair ... cell adhesion receptors consists of at least ... and b subunit that associate in a ... of the integrin family are based upon ...
... exchange media are rigid macroporous hydrophilic media. ... rates at moderate pressures, while the macroporous ... the hydrophilic matrix reduces nonspecific binding. Macro-Prep ... anion exchanger with very high flow rates ...
Biology Products: